These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25961749)

  • 1. Methadone for Patients with Malignant Psoas Syndrome: Case Series of Three Patients.
    Takase N; Ikegaki J; Nishimura H; Yuasa S; Ito Y; Kizawa Y
    J Palliat Med; 2015 Jul; 18(7):645-52. PubMed ID: 25961749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The management of malignant psoas syndrome: case reports and literature review.
    Agar M; Broadbent A; Chye R
    J Pain Symptom Manage; 2004 Sep; 28(3):282-93. PubMed ID: 15336342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of chronic neuropathic pain with methadone: a review of 13 cases.
    Altier N; Dion D; Boulanger A; Choinière M
    Clin J Pain; 2005; 21(4):364-9. PubMed ID: 15951657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer.
    Haumann J; Geurts JW; van Kuijk SM; Kremer B; Joosten EA; van den Beuken-van Everdingen MH
    Eur J Cancer; 2016 Sep; 65():121-9. PubMed ID: 27494037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Methadone for Patients With Neuropathic Pain Due to Neoplastic Brachial Plexopathy.
    Matsuda Y; Okayama S
    J Palliat Care; 2022 Apr; 37(2):77-82. PubMed ID: 33975501
    [No Abstract]   [Full Text] [Related]  

  • 6. Rotating to oral methadone in advanced cancer patients: a case series.
    Kilonzo I; Twomey F
    J Palliat Med; 2013 Sep; 16(9):1154-7. PubMed ID: 23631611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methadone versus Fentanyl in Patients with Radiation-Induced Nociceptive Pain with Head and Neck Cancer: A Randomized Controlled Noninferiority Trial.
    Haumann J; van Kuijk SMJ; Geurts JW; Hoebers FJP; Kremer B; Joosten EA; van den Beuken-van Everdingen MHJ
    Pain Pract; 2018 Mar; 18(3):331-340. PubMed ID: 28691202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Methadone in the treatment of chronic non-malignant pain].
    Bendiksen A; McGehee E; Handberg G
    Ugeskr Laeger; 2007 Apr; 169(17):1568-72. PubMed ID: 17484827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of methadone to another opioid in the management of moderate to severe cancer pain: a case series.
    Wallace E; Ridley J; Bryson J; Mak E; Zimmermann C
    J Palliat Med; 2013 Mar; 16(3):305-9. PubMed ID: 23391350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methadone and neuropathic cancer pain subcomponents: a prospective cohort pilot study.
    Fawoubo A; Perceau-Chambard É; Ruer M; Filbet M; Tricou C; Economos G
    BMJ Support Palliat Care; 2023 Dec; 13(e2):e273-e277. PubMed ID: 34620692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conservative Management of Neuropathic Pain in a Patient With Pancoast-Tobias Syndrome: A Case Report.
    Jones JH; Li A; Smith SK; Roy L; Fras AM
    A A Pract; 2018 Jul; 11(2):29-31. PubMed ID: 29634575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lesion site in malignant psoas syndrome influences the cancer pain intensity.
    Ishii K; Komatsu Y; Mori K; Nagaishi E; Matsuo K; Hashizume J; Ryu E; Ashizawa K; Hara T
    Ann Palliat Med; 2024 Jan; 13(1):57-61. PubMed ID: 38073291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study.
    Bruera E; Palmer JL; Bosnjak S; Rico MA; Moyano J; Sweeney C; Strasser F; Willey J; Bertolino M; Mathias C; Spruyt O; Fisch MJ
    J Clin Oncol; 2004 Jan; 22(1):185-92. PubMed ID: 14701781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperative N-methyl-D-aspartate (NMDA) receptor antagonism and mu-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic pain.
    Sotgiu ML; Valente M; Storchi R; Caramenti G; Biella GE
    Pharmacol Res; 2009 Oct; 60(4):284-90. PubMed ID: 19717013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent subcutaneous methadone administration in the management of cancer pain.
    Centeno C; Vara F
    J Pain Palliat Care Pharmacother; 2005; 19(2):7-12. PubMed ID: 16061456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Presentation and Management of Malignant Psoas Syndrome: A Scoping Review of Case Reports and Case Series.
    Suraj D; Zhang A; Appelbaum T; Ahmed N; Shih S; Gofman J; Kalenja K; Abrigo JN; Shaporova V; Mannan A; Jacobs RJ
    Cureus; 2023 Jul; 15(7):e41522. PubMed ID: 37551242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
    Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
    Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid plasma concentrations during a switch from transdermal fentanyl to methadone.
    Mercadante S; Villari P; Ferrera P; Casuccio A; Gambaro V
    J Palliat Med; 2007 Apr; 10(2):338-44. PubMed ID: 17472504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled-release oxycodone in the treatment of neuropathic pain of nonmalignant and malignant causes.
    Ong EC
    Oncology; 2008; 74 Suppl 1():72-5. PubMed ID: 18758202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The malignant psoas syndrome revisited: case report, mechanisms, and current therapeutic options.
    Stevens MJ; Atkinson C; Broadbent AM
    J Palliat Med; 2010 Feb; 13(2):211-6. PubMed ID: 20053159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.